News

Zentalis Pharmaceuticals' Upcoming Investor Conference Attendance

Zentalis Pharmaceuticals' Upcoming Investor Conference Attendance

Zentalis Pharmaceuticals Engaging with Investors

Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL), a forward-thinking clinical-stage biopharmaceutical company based in San Diego, is making strides in the oncology sector with its pioneering developments. The management team of Zentalis Pharmaceuticals is set to engage with investors in several upcoming noteworthy conferences, showcasing its commitment to advancing treatments for ovarian cancer and other tumor types.

Details of the Upcoming Conferences

Guggenheim's Healthcare Innovation Conference

The Zentalis team will take part in the second annual Guggenheim's Healthcare Innovation Conference. This event will occur in Boston, Massachusetts, where Zentalis has scheduled a fireside discussion. Attendees can expect insightful conversations on innovations in healthcare, specifically targeting ovarian cancer treatment advancements. The discussion is set for November 11, 2025, at 3:30 p.m. ET.

Stifel Healthcare Conference

In addition to the Guggenheim event, Zentalis Pharmaceuticals will present at the Stifel 2025 Healthcare Conference. This is an excellent opportunity for investors to hear directly from the company about their ongoing projects and future plans. The presentation is scheduled for November 12, 2025, at 8:00 a.m. ET, offering a comprehensive overview of Zentalis’s initiatives in oncology.

Webcasts and Presentations

For those unable to attend, Zentalis Pharmaceuticals has ensured access to live webcasts of both events. The recorded sessions will later be archived for convenient access under the "Events & Presentations" tab on the company's investor relations website. This accessibility underscores Zentalis' commitment to transparency and investor engagement.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals is at the forefront of developing innovative therapies in the oncology field. Their lead candidate, azenosertib (ZN-c3), is gaining attention as a potential first-in-class WEE1 inhibitor. It is specifically aimed at treating patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is currently undergoing various clinical trials as both a standalone treatment and in combination therapies across multiple tumor types.

Research indicates that azenosertib has shown promising anti-tumor activity and has been well tolerated in clinical settings. The extensive research and development at Zentalis aim not only to enhance treatment options for PROC but also to explore additional therapeutic potentials of azenosertib.

Company's Commitment to Innovation

Zentalis Pharmaceuticals actively strives to expand its R&D portfolio to address diverse oncology needs beyond ovarian cancer. With its robust expertise and adaptive approach, Zentalis is committed to transforming its scientific discoveries into impactful treatments. As they navigate regulatory landscapes, their focus remains on both innovation and patient care.

Contact Information

For further inquiries regarding Zentalis Pharmaceuticals, interested parties can reach out to Aron Feingold, the Vice President of Investor Relations & Corporate Communications, via email at ir@zentalis.com. The company encourages stakeholders to connect and stay updated on their developments in cancer solutions.

Frequently Asked Questions

What is Zentalis Pharmaceuticals known for?

Zentalis Pharmaceuticals is known for developing innovative cancer therapies, especially their lead candidate, azenosertib, which targets various tumor types.

When will the conferences take place?

The Guggenheim's Healthcare Innovation Conference is on November 11, 2025, and the Stifel Healthcare Conference is on November 12, 2025.

How can I access the presentations from the conferences?

Live webcasts of the events will be available on the company's investor relations website, along with archived recordings for later viewing.

Is azenosertib a standalone treatment?

Azenosertib is currently being evaluated as both a monotherapy and in combination with other treatments across different tumor types.

Who can I contact for more information about Zentalis?

For more information, you can contact Aron Feingold through the email: ir@zentalis.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

TCL Drives Fan Experience at FIBA Women's World Cup

Updated Category News Views 5

TCL's Slam Dunk on the Global Stage The FIBA Women's Basketball World Cup 2026 in Berlin is set to showcase some incredible talent, and TCL is right in the thick of it. As a FIBA Global Partner, they're spearheading a new wave of fan interactions with their TCLforHer initiative, focusing on tech-enabled fan experiences that go beyond just watching the game. This isn't...

Continue Reading
Dr. Rashedi Reveals Laughing Gas Safety for Kids

Updated Category News Views 3

Why Laughing Gas is a Game-Changer in Pediatric Dentistry You ever seen a kid freeze up like a deer in headlights at the dentist's office? I'm telling you, it's not just the sweet tooth nightmare but often the fear of that cold, intimidating chair. But let's talk about a game-changer: laughing gas or, known in the trade as nitrous oxide. Keeping Anxiety at Bay: The Role...

Continue Reading
See's Candies Data Breach Spurs Legal Scrutiny

Updated Category News Views 2

Data Breach Hits See's Candies Hard Amidst Ransomware Attack Alright, folks, here's a not-so-sweet tale to kick off your day — See's Candies has found itself in a bit of a pickle. A ransomware attack, the nasty kind that makes you double-check your locks and your passwords, has reportedly exposed the personal data of its customers and employees. We're talking names,...

Continue Reading
Midea's SpaceMaster Oven: Revolutionizing Home Pizza

Updated Category News Views 1

Oven Culture: Beyond Simple Baking When it comes to the kitchen, we're always promised more than we get. You know the spiel: the heart of the home, a place for traditions. But honestly? Most ovens are about as exciting as watching paint dry. Often too cramped, uneven, and a pain in the backside to preheat. But then, out of the burning blue, Midea comes along with their...

Continue Reading
Nocpix's Evolution: New Thermal Riflescope Unveiled

Updated Category News Views 2

Raising the Thermal Image Bar When Nocpix, known for cutting-edge electro-optical tech, teases a new thermal riflescope, it's time for hunters to perk up. This ain't just another gadget. We're talking about equipment that elevates precision and brings an edge to the field. Scheduled for hunters who mean business, this next-gen scope is destined to redefine what it means...

Continue Reading
Hims & Hers Faces Legal Storm Over Alleged Privacy Breaches

Updated Category News Views 4

Legal Storms Brew Over Alleged Privacy Breaches Well, here we go again, folks. Just when you think the waters are calming, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself in the thick of a nasty securities fraud class action lawsuit. Allegedly they've been less than honest with their customers' health info—something about sneaking around with people's sensitive data...

Continue Reading
PITAKA Redefines Tech Style With Berlin Launch Event

Updated Category News Views 1

Setting the Stage for Innovation Ah, Berlin in September—a city that’s hardly shy of showcasing avant-garde moves. And this time, we’re not talking about some cryptic art installation or underground techno rave. Nope, it's PITAKA making waves, transforming an edgy display at The Feuerle Collection. You see, on September 5, they unveiled their 'Wind Over Wheat'...

Continue Reading
Signant and Lothar Forge Future in Clinical Trials

Updated Category News Views 2

Breathing New Life into Clinical Trials Alright, folks, listen up. We've got a fresh collaboration cooking that could shake things up in the clinical trial sector. Signant Health, a heavyweight in clinical trial solutions, has teamed up with Lothar Medical, and they’ve hitched their wagons to launch something rather intriguing: the ALDS PRO pulmonary function tech. Let...

Continue Reading
viaim's AI Earbuds Snag IFA Awards, Launch On Indiegogo

Updated Category News Views 2

When the tech cosmos hands you two hefty IFA Innovation Awards, you know you’re onto something. viaim’s Rise wasn't just about slick marketing—it brought home the 'Best in Audio' and 'Best in Design' titles from IFA 2026, proving these earbuds are more than just another gadget. Key Innovations Behind the Accolades IFA is no small affair—it's a major tech trade...

Continue Reading
Softcare Facilitates Standards Delegation Visit to Senegal

Updated Category News Views 1

Ever seen a whole nation's hygiene industry getting a deep dive from not just one, but three major standards bodies? That's what just went down in Senegal. Softcare opened its doors wide to folks from the Senegalese Association for Standardization (ASN), the International Organization for Standardization (ISO), and the Swedish Institute for Standards (SIS). This was no...

Continue Reading

Top 5 Most Recently Viewed Articles

Jefferies Highlights Top Picks in Exposure Management Stocks

Updated Category News Views 159

Jefferies Identifies Promising Exposure Management Stocks Recently, Jefferies, a prominent investment bank, has begun its coverage of exposure management stocks, shedding light on a market that holds substantial promise despite facing some cyclical challenges. Analysts point to a strong future, estimating that the exposure management sector could reach a value of $53...

Continue Reading
MatSing and American Tower Team Up for Enhanced Connectivity

Updated Category News Views 251

MatSing struck a deal back in 2024 with American Tower to enhance mobile connectivity at Xcel Energy Center. This venue hosted over 150 events annually, welcoming around 1.7 million fans each year. In the digital era, spectators expect more than just the game; they crave seamless access to their devices during events. MatSing's CEO, Bo Larsson, highlighted that today’s...

Continue Reading
Exploring Market Sentiment Surrounding SoundHound AI Options

Updated Category News Views 143

Insights from the Options Market on SoundHound AI Investors are showing a notable bullish sentiment towards SoundHound AI. The recent trading activity in the options market reveals significant interest and varying expectations from market participants. Understanding Trading Patterns Upon reviewing the options history for SoundHound AI (SOUN), we identified 31 trades which...

Continue Reading
Datavault AI Welcomes Navy Veteran Pete Scobell as VP of Security

Updated Category News Views 179

Datavault AI Appoints Pete Scobell as Vice President of Global Security Datavault AI Inc. (Nasdaq: DVLT) is taking a significant step forward in its commitment to security by appointing U.S. Navy veteran Pete Scobell as Vice President of Global Security. This decision, announced by the company, highlights Datavault's focus on enhancing operations and reinforcing its...

Continue Reading
Nyxoah Launches Genio System to Transform Sleep Apnea Care

Updated Category News Views 104

Nyxoah's Groundbreaking FDA Approval for Genio System Nyxoah SA, a medical technology company based in Belgium, has made significant strides in the treatment of obstructive sleep apnea (OSA) with the recent FDA approval of its Genio system. This innovative device represents a new chapter in improving patient care for those suffering from OSA—a condition that disrupts...

Continue Reading